Literature DB >> 8521408

Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.

D Mukhopadhyay1, L Tsiokas, V P Sukhatme.   

Abstract

Angiogenesis, the development of new capillaries, is tightly controlled by the balance of positive and negative regulatory pathways. A newly described angiogenic factor, vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), binds exclusively to endothelial cells and promotes their proliferation. Here we have studied the role of p53, a tumor suppressor, and v-Src, an oncogene on VEGF regulation. Wild-type p53 down-regulated endogenous VEGF mRNA level, as well as VEGF promoter activity, in a dose-dependent manner, whereas mutant forms of p53 had no effect. Overexpression of v-Src, known to up-regulate VEGF expression, activated a VEGF promoter-luciferase construct in a dose-dependent manner. Moreover, v-Src, in the presence of wt-p53, was unable to activate transcription of the VEGF promoter. Collectively, these data suggest that wild-type p53 may play a role in suppressing angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  90 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma.

Authors:  Qi Niu; Zhao-You Tang; Zeng-Chen Ma; Lun-Xiu Qin; Lian-Hai Zhang
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 3.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

4.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 5.  p53 regulation of podosome formation and cellular invasion in vascular smooth muscle cells.

Authors:  Alan S Mak
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

6.  Kruppel-like factor 15 is critical for vascular inflammation.

Authors:  Yuan Lu; Lisheng Zhang; Xudong Liao; Panjamaporn Sangwung; Domenick A Prosdocimo; Guangjin Zhou; Alexander R Votruba; Leigh Brian; Yuh Jung Han; Huiyun Gao; Yunmei Wang; Koichi Shimizu; Kaitlyn Weinert-Stein; Maria Khrestian; Daniel I Simon; Neil J Freedman; Mukesh K Jain
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

7.  Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.

Authors:  I Hassan; A Wunderlich; E Slater; S Hoffmann; I Celik; A Zielke
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

8.  The transcription factor Net regulates the angiogenic switch.

Authors:  Hong Zheng; Christine Wasylyk; Abdelkader Ayadi; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Nicolas Wernert; Sauveur-Michel Maira; Marie-Christine Multon; Bohdan Wasylyk
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

Review 9.  Response of tumour cells to hypoxia: role of p53 and NFkB.

Authors:  J A Royds; S K Dower; E E Qwarnstrom; C E Lewis
Journal:  Mol Pathol       Date:  1998-04

Review 10.  microRNA-200b as a Switch for Inducible Adult Angiogenesis.

Authors:  Mithun Sinha; Subhadip Ghatak; Sashwati Roy; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2015-05-10       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.